Back to 
ZACKS INVESTMENT MANAGEMENT
ZACKS INVESTMENT MANAGEMENT
PTGXShowing 0 of 3 quarters
Position history for ZACKS INVESTMENT MANAGEMENT's holdings in PROTAGONIST THERAPEUTICS INC
No. Zacks Investment Management exited its PTGX (Protagonist Therapeutics) position in Q3 2023. Its Q2 2023 13F listed 11,168 shares worth $308,448. Zacks Investment Management first reported PTGX in Q1 2023 and held it in 2 quarterly 13F filings.
Current Value
-
Current Shares
-
Total Value Change
$0
Total Shares Change
0
No position history available for this security.
Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.